Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REC-1245 |
| Synonyms | |
| Therapy Description |
REC-1245 is a molecular glue degrader that induces DCAF15-dependent proteasomal degradation of RBM39, which potentially results in altered gene expression, reduced DNA damage response, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REC-1245 | REC 1245|REC1245 | REC-1245 is a molecular glue degrader that induces DCAF15-dependent proteasomal degradation of RBM39, which potentially results in altered gene expression, reduced DNA damage response, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06678659 | Phase Ib/II | REC-1245 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (DAHLIA) | Recruiting | USA | CAN | 0 |